|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33.
2022.PubMed/NCBI
|
|
2
|
Wang B, Guo H, Xu H, Yu H, Chen Y and Zhao
G: Research progress and challenges in the treatment of central
nervous system metastasis of non-small cell lung cancer. Cells.
10:26202021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mulshine JL, Pyenson B, Healton C, Aldige
C, Avila RS, Blum T, Cham M, de Koning HJ, Fain SB, Field JK, et
al: Paradigm shift in early detection: Lung cancer screening to
comprehensive CT screening. Eur J Cancer. 218:1152642025.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Yan B and He S: Advances and
challenges in the treatment of lung cancer. Biomed Pharmacother.
169:1158912023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lahiri A, Maji A, Potdar PD, Singh N,
Parikh P, Bisht B, Mukherjee A and Paul MK: Lung cancer
immunotherapy: Progress, pitfalls, and promises. Mol Cancer.
22:402023. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
McLouth LE, Gabbard J, Levine BJ, Golden
SL, Lycan TW, Petty WJ and Weaver KE: Prognostic awareness,
palliative care use, and barriers to palliative care in patients
undergoing immunotherapy or chemo-immunotherapy for metastatic lung
cancer. J Palliat Med. 26:831–836. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Seute T, Leffers P, ten Velde GP and
Twijnstra A: Neurologic disorders in 432 consecutive patients with
small cell lung carcinoma. Cancer. 100:801–806. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Maldonado F, Gonzalez-Ling A, Oñate-Ocaña
LF, Cabrera-Miranda LA, Zatarain-Barrón ZL, Turcott JG,
Flores-Estrada D, Lozano-Ruiz F, Cacho-Díaz B and Arrieta O:
Prophylactic cranial irradiation in patients with high-risk
metastatic non-small cell lung cancer: Quality of life and
neurocognitive analysis of a randomized phase II study. Int J
Radiat Oncol Biol Phys. 111:81–92. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rangachari D, Yamaguchi N, VanderLaan PA,
Folch E, Mahadevan A, Floyd SR, Uhlmann EJ, Wong ET, Dahlberg SE,
Huberman MS and Costa DB: Brain metastases in patients with
EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung
Cancer. 88:108–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu F, Fan J, He Y, Xiong A, Yu J, Li Y,
Zhang Y, Zhao W, Zhou F, Li W, et al: Single-cell profiling of
tumor heterogeneity and the microenvironment in advanced non-small
cell lung cancer. Nat Commun. 12:25402021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lim ZF and Ma PC: Emerging insights of
tumor heterogeneity and drug resistance mechanisms in lung cancer
targeted therapy. J Hematol Oncol. 12:1342019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan K, Concannon K, Li J, Zhang J, Heymach
JV and Le X: Emerging therapeutics and evolving assessment criteria
for intracranial metastases in patients with oncogene-driven
non-small-cell lung cancer. Nat Rev Clin Oncol. 20:716–732. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pike LRG, Miao E, Boe LA, Patil T, Imber
BS, Myall NJ, Pollom EL, Hui C, Qu V, Langston J, et al: Tyrosine
kinase inhibitors with and without up-front stereotactic
radiosurgery for brain metastases from EGFR and ALK oncogene-driven
non-small cell lung cancer (TURBO-NSCLC). J Clin Oncol.
42:3606–3617. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jünger ST, Schödel P, Ruess D, Ruge M,
Brand JS, Wittersheim M, Eich ML, Schmidt NO, Goldbrunner R, Grau S
and Proescholdt M: Timing of development of symptomatic brain
metastases from non-small cell lung cancer: Impact on symptoms,
treatment, and survival in the era of molecular treatments. Cancers
(Basel). 12:36182020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lancia A, Merizzoli E and Filippi AR: The
8th UICC/AJCC TNM edition for non-small cell lung cancer staging:
Getting off to a flying start? Ann Transl Med. 7 (Suppl
6):S2052019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Moon SW, Choi SY and Moon MH: Effect of
invasive mucinous adenocarcinoma on lung cancer-specific survival
after surgical resection: A population-based study. J Thorac Dis.
10:3595–3608. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li J, Zhang X, Wang Y, Jin Y, Song Y and
Wang T: Clinicopathological characteristics and prognosis of
synchronous brain metastases from non-small cell lung cancer
compared with metachronous brain metastases. Front Oncol.
14:14007922024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Williams TM, Miller E, Welliver M,
Brownstein J, Otterson G, Owen D, Haglund K, Shields P, Bertino E,
Presley C, et al: A phase 2 trial of primary tumor stereotactic
body radiation therapy boost before concurrent chemoradiation for
locally advanced non-small cell lung cancer. Int J Radiat Oncol
Biol Phys. 120:681–694. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gaspar L, Scott C, Rotman M, Asbell S,
Phillips T, Wasserman T, McKenna WG and Byhardt R: Recursive
partitioning analysis (RPA) of prognostic factors in three
radiation therapy oncology group (RTOG) brain metastases trials.
Int J Radiat Oncol Biol Phys. 37:745–751. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frappaz D, Bonneville-Levard A, Ricard D,
Carrie S, Schiffler C, Xuan KH and Weller M: Assessment of
Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour
patients: The role of clinician bias. Support Care Cancer.
29:1883–1891. 2021.PubMed/NCBI
|
|
21
|
Lorenzoni J, Devriendt D, Massager N,
David P, Ruíz S, Vanderlinden B, Van Houtte P, Brotchi J and
Levivier M: Radiosurgery for treatment of brain metastases:
Estimation of patient eligibility using three stratification
systems. Int J Radiat Oncol Biol Phys. 60:218–224. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sperduto PW, Kased N, Roberge D, Xu Z,
Shanley R, Luo X, Sneed PK, Chao ST, Weil RJ, Suh J, et al: Summary
report on the graded prognostic assessment: An accurate and facile
diagnosis-specific tool to estimate survival for patients with
brain metastases. J Clin Oncol. 30:419–425. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sperduto PW, Yang TJ, Beal K, Pan H, Brown
PD, Bangdiwala A, Shanley R, Yeh N, Gaspar LE, Braunstein S, et al:
Estimating survival in patients with lung cancer and brain
metastases: An update of the graded prognostic assessment for lung
cancer using molecular markers (lung-molGPA). JAMA Oncol.
3:827–831. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cho A, Gatterbauer B, Chen Y, Jankowski T,
Haider L, Tögl S, Kapfhammer I, Schreder M, Kirchbacher K,
Zöchbauer-Müller S, et al: Effect of cumulative dexamethasone dose
on the outcome of patients with radiosurgically treated brain
metastases in the era of modern oncological therapy. J Neurosurg.
143:384–395. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gillespie BW, Chen Q, Reichert H,
Franzblau A, Hedgeman E, Lepkowski J, Adriaens P, Demond A,
Luksemburg W and Garabrant DH: Estimating population distributions
when some data are below a limit of detection by using a reverse
Kaplan-Meier estimator. Epidemiology. 21 (Suppl 4):S64–S70. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Surjanovic N, Lockhart RA and Loughin TM:
A generalized Hosmer-Lemeshow goodness-of-fit test for a family of
generalized linear models. Test (Madr). 33:589–608. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jewell ES, Maile MD, Engoren M and Elliott
M: Net reclassification improvement. Anesth Analg. 122:818–824.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schröder C, Windisch P, Lütscher J,
Zwahlen DR and Förster R: Validation and discussion of clinical
practicability of the 2022 graded prognostic assessment for NSCLC
adenocarcinoma patients with brain metastases in a routine clinical
cohort. Front Oncol. 13:10425482023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chinese Association for Clinical
Oncologists; Medical Oncology Branch of Chinese International
Exchange and Promotion Association for Medical and Healthcare, .
Clinical practice guideline for brain metastases of lung cancer in
China (2021 version). Zhonghua Zhong Liu Za Zhi. 43:269–281.
2021.(In Chinese). PubMed/NCBI
|
|
30
|
Rades D, Hansen HC, Schild SE and Janssen
S: A new diagnosis-specific survival score for patients to be
irradiated for brain metastases from non-small cell lung cancer.
Lung. 197:321–326. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sperduto PW, De B, Li J, Carpenter D,
Kirkpatrick J, Milligan M, Shih HA, Kutuk T, Kotecha R, Higaki H,
et al: Graded prognostic assessment (GPA) for patients with lung
cancer and brain metastases: Initial report of the small cell lung
cancer GPA and update of the non-small cell lung cancer GPA
including the effect of programmed death ligand 1 and other
prognostic factors. Int J Radiat Oncol. 114:60–74. 2022. View Article : Google Scholar
|
|
32
|
Sperduto PW, Mesko S, Li J, Cagney D,
Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, et al:
Survival in patients with brain metastases: Summary report on the
updated diagnosis-specific graded prognostic assessment and
definition of the eligibility quotient. J Clin Oncol. 38:3773–3784.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li R, Zhang SR, Liu XF, Zhang JW, Zhao JY,
Bai P and Zhang XC: Prognostic factors for non-small cell lung
cancer patients with central nervous system metastasis with
positive driver genes. Zhonghua Yi Xue Za Zhi. 103:1202–1209.
2023.PubMed/NCBI
|
|
34
|
Zhang M, Tong J, Ma W, Luo C, Liu H, Jiang
Y, Qin L, Wang X, Yuan L, Zhang J, et al: Predictors of lung
adenocarcinoma with leptomeningeal metastases: A 2022
targeted-therapy-assisted molGPA model. Front Oncol. 12:9038512022.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mulvenna PM, Holt T and Stephens R:
Response to ‘Diagnosis-specific prognostic factors, indexes, and
treatment outcomes for patients with newly diagnosed brain
metastases: A multi-institutional analysis of 4,259 patients’. (Int
J Radiat Oncol Biol Phys 2010:77:655-661). Int J Radiat Oncol Biol
Phys. 81:11942011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yamamoto M, Kawabe T, Higuchi Y, Sato Y,
Barfod BE, Kasuya H and Urakawa Y: Validity of three recently
proposed prognostic grading indexes for breast cancer patients with
radiosurgically treated brain metastases. Int J Radiat Oncol Biol
Phys. 84:1110–1115. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Winslow N, Boyle J, Miller W, Wang Y,
Geoffroy F and Tsung AJ: Development of brain metastases in
non-small-cell lung cancer: High-risk features. CNS Oncol.
13:23958042024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schmid S, Garcia M, Zhan L, Cheng S, Khan
K, Chowdhury M, Sabouhanian A, Herman J, Walia P, Strom E, et al:
Outcomes with non-small cell lung cancer and brain-only metastasis.
Heliyon. 10:e370822024. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Higaki H, Nishioka K, Otsuka M, Nishikawa
N, Shido M, Minatogawa H, Nishikawa Y, Takashina R, Hashimoto T,
Katoh N, et al: Brain metastases in Japanese NSCLC patients:
Prognostic assessment and the use of osimertinib and immune
checkpoint inhibitors-retrospective study. Radiat Oncol. 18:252023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liang L, Wang Z, Duan H, He Z, Lu J, Jiang
X, Hu H, Li C, Yu C, Zhong S, et al: Survival benefits of
radiotherapy and surgery in lung cancer brain metastases with poor
prognosis factors. Curr Oncol. 30:2227–2236. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ohe Y, Imamura F, Nogami N, Okamoto I,
Kurata T, Kato T, Sugawara S, Ramalingam SS, Uchida H, Hodge R, et
al: Osimertinib versus standard-of-care EGFR-TKI as first-line
treatment for EGFRm advanced NSCLC: FLAURA Japanese subset. Jpn J
Clin Oncol. 49:29–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu S, Dong X, Jian H, Chen J, Chen G, Sun
Y, Ji Y, Wang Z, Shi J, Lu J, et al: AENEAS: A randomized phase III
trial of aumolertinib versus gefitinib as first-line therapy for
locally advanced or metastaticnon-small-cell lung cancer with EGFR
exon 19 deletion or L858R mutations. J Clin Oncol. 40:3162–3171.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shi Y, Chen G, Wang X, Liu Y, Wu L, Hao Y,
Liu C, Zhu S, Zhang X, Li Y, et al: Central nervous system efficacy
of furmonertinib (AST2818) versus gefitinib as first-line treatment
for EGFR-mutated NSCLC: Results from the FURLONG study. J Thorac
Oncol. 17:1297–1305. 2022. View Article : Google Scholar : PubMed/NCBI
|
